Trials / Completed
CompletedNCT00548925
A Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain
A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of ABT-894 Versus Placebo in Subjects With Diabetic Neuropathic Pain
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 124 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of a 6 mg twice a day dose of an investigational product in subjects with diabetic neuropathy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-894 | 6 mg BID tablets, 8 weeks of treatment |
| DRUG | placebo | BID tablets, 8 weeks of treatment |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2007-10-24
- Last updated
- 2013-01-21
Locations
29 sites across 7 countries: United States, Czechia, France, Germany, Italy, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00548925. Inclusion in this directory is not an endorsement.